EXPrESSIVE Phase 3 Trial Countries



EXPrESSIVE-11

- Approximately 4390 participants
- Cisgender men, MSM, transgender men and women, gender non-binary persons who could benefit from PrEP
- ClinicalTrials.gov Study Record

EXPrESSIVE-10

- Approximately 4580 participants
- Cisgender adolescent girls, young women, and women who could benefit from PrEP
- ClinicalTrials.gov Study Record

Seventeen countries in total are hosting sites for Merck's Phase 3 trials of the monthly PrEP pill, MK-8527. Launch expected Q3 2025.

August 2025

AVAC
Advocacy. Access. Equity.